Telix Appoints David Gill as Non-Executive Director
Rhea-AI Summary
Telix (ASX/NASDAQ: TLX) announced the appointment of David Gill as a Non-Executive Director, effective May 11, 2026, as part of Board expansion and succession planning.
Mr. Gill, a life sciences executive with over 35 years of senior management and financial leadership experience, is expected to be appointed Chair in due course, succeeding Dr. Mark Nelson, who will remain on the Board as a NED.
Mr. Gill's background includes CFO/President roles at multiple public companies, board roles in U.S. life sciences firms, and degrees from Wake Forest and Emory.
Positive
- Board expanded with NED appointment effective May 11, 2026
- Chair succession planned with David Gill expected to succeed Mark Nelson
- David Gill brings over 35 years of industry leadership experience
- Notable U.S. capital markets and CFO experience at public life sciences companies
Negative
- Near-term governance transition risk as chair succession is implemented
- Potential for strategic adjustment during Board expansion and further appointments
News Market Reaction – TLX
On the day this news was published, TLX declined 1.19%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TLX declined 3.45% while peers were mixed: RARE (+2.15%), ZLAB (+2.26%), APLS (+0.1%), and LGND (-1.91%) and MLTX (-8.93%). With no peers in the momentum scanner and no same-day peer news, TLX’s move appears stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 15 | NDA resubmission | Positive | -0.3% | Resubmitted TLX101-Px NDA with added data after prior Complete Response Letter. |
| Mar 09 | Phase 3 trial update | Positive | +5.5% | ProstACT Global Phase 3 Part 1 met primary safety and dosimetry objectives. |
| Mar 01 | Investor webinar | Neutral | -2.8% | Announced educational webinar on future of prostate imaging for investors. |
| Feb 27 | AI research collaboration | Positive | -3.6% | Joined PROMISE-PET registry to develop AI prognostic models using PSMA-PET. |
| Feb 20 | Conference participation | Neutral | +14.6% | Planned presentations at Oppenheimer and TD Cowen investor conferences. |
Recent news often produced price moves that diverged from the apparent positivity of the announcements, with only one clear alignment on favorable clinical data.
Over the past months, Telix has reported several strategic and clinical milestones. A Q3 2026 New Drug Application resubmission for TLX101-Px followed a prior Complete Response Letter, yet the stock slipped modestly. Positive Part 1 results from the ProstACT Global Phase 3 trial on Mar 9, 2026 drove a 5.47% gain, the only clearly aligned reaction. Collaboration on AI-enabled PSMA-PET imaging and multiple investor events around Feb–Mar 2026 saw mixed to negative reactions, suggesting investor sensitivity and inconsistent price responses to otherwise constructive updates relative to today’s governance-focused board appointment.
Market Pulse Summary
This announcement expands Telix’s board with a seasoned Non-Executive Director bringing 35 years of life sciences and financial leadership experience, including roles at publicly traded companies. In light of earlier milestones such as Q2 2025 revenue of US$240 million and 63% year-over-year growth, the move underscores an emphasis on governance and U.S. capital markets expertise. Investors may watch how this appointment supports strategic execution alongside upcoming clinical, regulatory, and commercial updates.
Key Terms
non-executive director financial
radiopharmaceuticals medical
AI-generated analysis. Not financial advice.
MELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 20261. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as a NED.
Mr. Gill is a life sciences executive with over 35 years’ experience in senior general management and financial leadership roles across commercial and clinical-stage biopharmaceutical (including radiopharmaceuticals) and medical device companies. He currently serves on the boards of Evolus, Inc. (NASDAQ: EOLS), Allucent LLC, Bridge to Life Ltd, RapidPulse Inc. and huMannity Medtec (formerly Alfred Mann Foundation), and was until recently a board member of Y-mAbs Therapeutics, Inc., Strongbridge Biopharma plc, Alpha Source Inc, Healthtronics, Inc, and Perimetrics, LLC.
Mr. Gill brings deep expertise in capital markets, scaling businesses, governance and corporate turn-around strategy and has served as Chief Financial Officer or President of multiple publicly traded companies, including EndoChoice Holdings, Inc. (acquired by Boston Scientific), INC Research (now Syneos Health), and CTI Molecular Imaging (acquired by Siemens). He holds a B.S. in Accounting from Wake Forest University and an MBA from Emory University.
Telix Interim Chair, Mark Nelson, commented, “We are pleased to welcome David to the Board, where his strong financial expertise and deep knowledge of U.S. capital markets will be highly valuable. We intend to further strengthen the Board through additional appointments aligned with our growth trajectory and governance needs as a dual-listed company.”
About Telix Pharmaceuticals Limited
Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
| Telix Investor Relations (Global) Ms. Kyahn Williamson SVP Investor Relations and Corporate Communications kyahn.williamson@telixpharma.com | Telix Investor Relations (Australia) Ms. Charlene Jaw Associate Director Investor Relations charlene.jaw@telixpharma.com | Telix Investor Relations (U.S.) Ms. Annie Kasparian Director Investor Relations and Corporate Communications annie.kasparian@telixpharma.com |
Media Contact
Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com
This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
1 Subject to grant of Australian Director Identification number.
